BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares gapped down prior to trading on Wednesday . The stock had previously closed at $5.18, but opened at $5.23. BioCryst Pharmaceuticals shares last traded at $5.36, with a volume of 7,714,030 shares trading hands.
A number of research analysts have commented on the company. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, May 19th. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Sunday, May 28th. Royal Bank Of Canada initiated coverage on BioCryst Pharmaceuticals in a research note on Thursday. They issued a “sector perform” rating on the stock. Finally, BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $9.13.
The company’s market cap is $415.01 million. The firm’s 50-day moving average price is $4.86 and its 200-day moving average price is $6.09.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. During the same period in the prior year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.
Several institutional investors have recently modified their holdings of BCRX. Legal & General Group Plc grew its stake in shares of BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 860 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 45 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of BioCryst Pharmaceuticals in the second quarter worth $126,000. Janney Montgomery Scott LLC grew its stake in shares of BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Pacad Investment Ltd. bought a new stake in shares of BioCryst Pharmaceuticals in the second quarter worth $196,000. 86.23% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Shares Gap Down to $5.23” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/15/biocryst-pharmaceuticals-inc-bcrx-shares-gap-down-to-5-23.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.